Monsanto and AHP call off merger
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.THE US pharmaceuticals company American Home Products and the chemicals and biotechnology group Monsanto stunned Wall Street yesterday by calling off their $34bn merger.
In a brief statement to the New York stock exchange the two companies said a merger would not have been in the best interests of shareholders.
This is the third mega-merger in the pharmaceuticals industry to have been called off this year. SmithKline Beecham scrapped plans to merge with AHP in January and announced instead that it intended to merge with Glaxo Wellcome. This deal was also abandoned.
The collapse of the AHP-Monsanto merger hit shares in both companies and led to renewed speculation that AHP might try to rekindle a deal with SmithKline Beecham.
But AHP said that it did not have another partner lined up and analysts cast doubt on whether SmithKline Beecham would be interested in reviving talks with the US company.
The merger of AHP and Monsanto was first unveiled in June. Although it would have resulted in Monsanto shareholders owning 35 per cent of the enlarged group, it would have had an equal number of seats on the board and Robert Shapiro, Monsanto's chairman, and John Stafford, AHP's chief executive, would have served as co-chairmen and co-chief executives.
AHP, based in Madison, New Jersey, makes pharmaceutical products, including Advil pain reliever, Robitussin cough syrup and prescription drugs. St Louis-based Monsanto's products include the artificial sweetener NutraSweet, agricultural products, and drugs, including the sleeping pill Ambien.
Rumours had swirled in financial markets earlier this month that the deal was in jeopardy.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments